Page last updated: 2024-12-05

quinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Quinic acid is a naturally occurring hydroxycinnamic acid found in a variety of plants, including coffee beans, fruits, and vegetables. It is a key intermediate in the biosynthesis of important secondary metabolites, such as shikimic acid, which is used in the production of the antiviral drug oseltamivir (Tamiflu). Quinic acid has also been investigated for its potential health benefits, including its antioxidant, anti-inflammatory, and anti-diabetic properties. Research on quinic acid focuses on its role in plant metabolism, its potential therapeutic applications, and its interactions with other bioactive compounds. In addition, quinic acid is being studied for its potential use in the development of new drugs and dietary supplements.'

(-)-quinic acid : The (-)-enantiomer of quinic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CinchonagenusA genus of rubiaceous South American trees that yields the toxic CINCHONA ALKALOIDS from their bark; QUININE; QUINIDINE; chinconine, cinchonidine and others are used to treat MALARIA and CARDIAC ARRHYTHMIAS.[MeSH]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]

Cross-References

ID SourceID
PubMed CID6508
CHEMBL ID465398
CHEBI ID17521
SCHEMBL ID39556
SCHEMBL ID1286207
SCHEMBL ID1286208
SCHEMBL ID7923331
SCHEMBL ID23845421
MeSH IDM0018339

Synonyms (112)

Synonym
MLS002207201
smr001306762
1l-1(oh),3,4/5-tetrahydroxycyclohexanecarboxylic acid
CHEBI:17521 ,
(1s,3r,4s,5r)-1,3,4,5-tetrahydroxycyclohexanecarboxylic acid
d-quinic acid
DIVK1C_006515 ,
KBIO1_001459
SDCCGMLS-0066613.P001 ,
ACON1_001963
SPECTRUM5_000434
nsc 59258
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (1r-(1-alpha,3-alpha,4-alpha,5-beta))-
(-)-1,3,4,5-tetrahydroxycyclohexanecarboxylic acid
einecs 201-072-8
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (1r-(1alpha,3alpha,4alpha,5beta))-
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (-)-
1,3,4,5-tetrahydroxycyclohexanecarboxylic acid (1r-(1alpha,3alpha,4alpha,5beta)
chinasaure
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (1theta-(1alpha,3alpha,4alpha,5beta))-
nsc-59258
SPECTRUM4_001867
SPECTRUM_001413
BSPBIO_003137
NCGC00178246-01
NCGC00178246-02
NSC59258 ,
d-(-)-quinic acid
(3r,5r)-1,3,4,5-tetrahydroxycyclohexanecarboxylic acid
(1r,3r,4r,5r)-(-)-tetrahydroxycyclohexanecarboxylic acid
cyclohexanecarboxylic acid,3,4,5-tetrahydroxy-, (1.alpha.,3.alpha.,4.alpha.,5.beta.)-
nsc-1115
C00296
77-95-2
quinic acid ,
l-quinic acid
nsc1115 ,
kinic acid
chinic acid
(-)-quinic acid
MEGXP0_001735
d-(-)-quinic acid, 98%
KBIO2_004461
KBIO3_002357
KBIO2_001893
KBIOSS_001893
KBIO2_007029
KBIOGR_002336
SPECTRUM2_001790
SPBIO_001719
SPECPLUS_000419 ,
SPECTRUM3_001349
SPECTRUM310018
883DE888-EC82-454C-B69C-8B1F9AC6DAA9
qic ,
(3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (1.alpha., 3.alpha.,4.alpha.,5.beta.)-
BMSE000306
Q0009
CHEMBL465398
rel-quinic acid
STK801928
AKOS005622501
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (1alpha,3r,4alpha,5r)-
058c04bgyi ,
unii-058c04bgyi
S3886
CCG-38438
BP-12304
4GUI
4IUO
(-)-quinic acid (constituent of cranberry liquid preparation) [dsc]
cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (1.alpha.,3r,4.alpha.,5r)-
quinic acid [mi]
quinic acid [inci]
quinic acid [usp-rs]
quinic acid [who-dd]
BBL033519
SCHEMBL39556
SCHEMBL1286207
SCHEMBL1286208
SCHEMBL7923331
W-203791
d-(-)-quinic-acid
(-)quinic acid
d(-)-quinic acid
mfcd00003864
(3r,5r)-1,3,4,5-tetrakis(oxidanyl)cyclohexane-1-carboxylic acid
(-) quinic acid, analytical standard
d-(-)-quinic acid, purum, >=98.0% (t)
quinic acid, united states pharmacopeia (usp) reference standard
kinate
chinate
bdbm50485632
quinic acid, pharmaceutical secondary standard; certified reference material
(1|a,3r,4|a,5r)-1,3,4,5-tetrahydroxycyclohexanecarboxylic acid
AAWZDTNXLSGCEK-LNVDRNJUSA-N
DTXSID70998288
Q424931
CS-0008991
HY-N0464
VS-12119
(1s,3r,4s,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid
quinicacid
HMS3885A12
H10089
SCHEMBL23845421
EN300-197153
(3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylicacid
quinic acid, d-
Z1255382952
PD087258

Research Excerpts

Overview

Quinic acid is a key metabolite associated with the shikimate pathway existing only in plants. It is responsible for essential amino acid biosynthesis such as tryptophan and tyrosine.

ExcerptReferenceRelevance
"Quinic acid is a key metabolite associated with the shikimate pathway existing only in plants, and it is responsible for essential amino acid biosynthesis such as tryptophan, phenylalanine and tyrosine."( Health consequences of catabolic synthesis of hippuric acid in humans.
Pero, RW, 2010
)
1.08
"Quinic acid (QA) is an active ingredient of Cat's Claw (Uncaria tomentosa), which is found to be active in enhancing DNA repair and immunity in model systems and able to generate neuroprotective effects in neurons. "( Quinic acid could be a potential rejuvenating natural compound by improving survival of Caenorhabditis elegans under deleterious conditions.
Zhang, J; Zhang, L; Zhao, B; Zhao-Wilson, X, 2012
)
3.26

Effects

Quinic acid (QA) has been shown to possess radioprotection, anti-neuroinflammatory, and anti-oxidant activities. An anti-vascular inflammatory effect has not been reported. Quinic acid has been detected by color reaction and isochlorogenic by ultra-violet light.

ExcerptReferenceRelevance
"Quinic acid (QA) has been shown to possess radioprotection, anti-neuroinflammatory, and anti-oxidant activities; however, an anti-vascular inflammatory effect has not been reported."( Quinic acid inhibits vascular inflammation in TNF-α-stimulated vascular smooth muscle cells.
Jang, SA; Jeon, H; Kang, SC; Koo, HJ; Kwon, JE; Park, B; Park, DW; Sohn, EH; Song, HS, 2017
)
2.62
"Quinic acid has been detected by color reaction and isochlorogenic by ultra-violet light."( [Quinic and isochlorogenic acids in sunflower seeds (Helianthus annuus Lin.)].
Blanc, A; Lanet, J; Mourgue, M; Steinmetz, MD, 1975
)
0.98

Toxicity

ExcerptReferenceRelevance
" AlQ was significantly less toxic than Al-S during both short- (3h) and long-term (24h) incubations."( Aluminum does not enhance beta-amyloid toxicity in rat hippocampal cultures.
Drever, BD; Nday, CM; Platt, B; Salifoglou, T, 2010
)
0.36
" However, an undesired adverse effect of MPA impedes its application in the clinics for post-transplant patients."( Synthesis and Characterization of a Novel Mycophenolic Acid-Quinic Acid Conjugate Serving as Immunosuppressant with Decreased Toxicity.
Dong, Y; Mahato, RI; Peng, Y, 2015
)
0.66

Pharmacokinetics

Caffeoylquinic acids have potential pharmacodynamic effects in vitro. Pharmacokinetic studies of the caffeoyl Quinic acids are needed.

ExcerptReferenceRelevance
" Various potential pharmacodynamic effects have been observed in vitro for mono- and dicaffeoylquinic acids (e."( Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans.
Derendorf, H; Drewelow, B; Müller, SC; Ploch, M; Veit, M; Windeck, T; Wittemer, SM, 2005
)
0.8
" Half-life of KZ-41 was ≈3 hr after either intravenous or oral administration."( Preclinical pharmacokinetics of the radiomitigator KZ-41 in rats.
Miller, DD; Presley, CS; Thompson, KE; Yates, CR; Zeng, K, 2011
)
0.37
" Therefore, pharmacokinetic studies of the caffeoylquinic acids are needed."( A rapid and sensitive UPLC-MS/MS method for quantification of two caffeoylquinic acids and four main active components in rat plasma after an intravenous administration of Qingkailing injection and its application to a pharmacokinetic study.
Gao, X; Guo, M; Liu, H; Peng, L; Song, Y; Su, J; Zhang, L; Zhao, L, 2014
)
0.89
" This study provided the pharmacokinetic profiles and the tissue regional distribution of MCQAs, DCQAs and caffeic acid."( Comparative pharmacokinetics and tissue distribution study of mono-, and di-caffeoylquinic acids isomers of Ainsliaea fragrans Champ by a fast UHPLC-MS/MS method.
Feng, Y; Huang, J; Song, Y; Su, D, 2014
)
0.63
" We conducted a phase I and pharmacokinetic study with the phenolic compound-enriched product extracted from Erigeron breviscapus, Erigerontis hydroxybenzenes injection (EHI), in healthy Chinese volunteers."( Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers.
Dai, GL; Fang, ZY; Ju, WZ; Liu, F; Liu, SJ; Wu, T; Xiong, NN; Zhang, J; Zhao, Y; Zhou, L, 2015
)
0.42
" The method validation results demonstrated that the proposed method was sensitive, specific, and reliable, which was successfully applied to the pharmacokinetic study of four components after oral administration of Echinacea purpurea extract."( Simultaneous determination and pharmacokinetic study of four phenol compounds in rat plasma by ultra-high performance liquid chromatography with tandem mass spectrometry after oral administration of Echinacea purpurea extract.
Du, Y; Gan, C; Gao, M; Liu, L; Wang, L; Wu, L; Yang, C, 2016
)
0.43
" The pharmacokinetic parameters of the 3,4-, 3,5- and 4,5- DCQA were remarkably different from those in normal rats."( Simultaneous determination of three di-caffeoylquinic acids by UHPLC-MS/MS in rat plasma and its application to a comparative pharmacokinetic study in normal and acute lung injury rat.
Ma, C; Wang, Y; Wu, X; Xiao, W; Xiong, Z, 2017
)
0.71
" This method was successfully applied to pharmacokinetic study of CGA in Chinese subjects with advanced solid tumor after intramuscular injection administration of Chlorogenic acid for injection (CAFI)."( Development of an LC-MS/MS method for quantitative analysis of Chlorogenic acid in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor.
Bing Xu, G; Gao, J; Gong, JF; Kou, FR; Li, Y; Shen, L; Yang, F; Zhang, C, 2020
)
0.56
"The present study investigated the pharmacodynamic material basis of Laportea bulbifera in the treatment of rheumatoid arthritis."( [Potential pharmacodynamic substances of Laportea bulbifera in treatment of rheumatoid arthritis based on serum pharmacochemistry and pharmacology].
Chen, SY; Chen, Y; Gong, ZP; Huang, Y; Lan, YY; Li, YT; Tang, J; Wang, YL; Wu, D; Zhang, Q; Zheng, L, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, drug-drug Interactions (DDIs) between DCQAs and possible concomitant drugs were not fully understood in clinic."( Organic anion transporter 3 (OAT3)-mediated transport of dicaffeoylquinic acids and prediction of potential drug-drug interaction.
Deng, S; Feng, L; Huo, X; Lin, Y; Ma, X; Ren, J; Sun, C; Sun, Q; Tian, X; Wang, C; Wang, Y; Zhang, B; Zhang, Z, 2019
)
0.75

Bioavailability

ExcerptReferenceRelevance
" Such a high abundance of microbial metabolites shows that the bioavailability of chlorogenic acid depends largely on its metabolism by the gut microflora."( Chlorogenic acid bioavailability largely depends on its metabolism by the gut microflora in rats.
Besson, C; Gonthier, MP; Rémésy, C; Scalbert, A; Verny, MA, 2003
)
0.32
"Dietary CQA reduces oxidative stress and improves nitric oxide bioavailability by inhibiting excessive production of reactive oxygen species in the vasculature, and leads to the attenuation of endothelial dysfunction, vascular hypertrophy, and hypertension in spontaneously hypertensive rats."( Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats.
Fujii, A; Jokura, H; Saito, I; Suzuki, A; Tokimitsu, I; Yamamoto, M; Yamamoto, N, 2006
)
0.33
" However, data on the bioavailability of CGA from green coffee in humans are inexistent."( Chlorogenic acids from green coffee extract are highly bioavailable in humans.
Donangelo, CM; Farah, A; Lafay, S; Monteiro, M, 2008
)
0.35
" In future, this analytical method will give more confidence in compound identification to provide a more comprehensive assessment of coffee polyphenol bioavailability studies in humans."( Identification of novel circulating coffee metabolites in human plasma by liquid chromatography-mass spectrometry.
Dionisi, F; Guy, P; Nagy, K; Redeuil, K; Renouf, M; Rezzi, S; Smarrito-Menozzi, C; Williamson, G, 2011
)
0.37
" In conclusion, hydrolysis of the extract of Ilex paraguariensis is a strategy to improve its bioavailability and in vivo antioxidant activity."( Hydrolysis influence on phytochemical composition, antioxidant activity, plasma concentration, and tissue distribution of hydroethanolic Ilex paraguariensis extract components.
Almeida, RL; Barros, SB; Rivelli, DP; Ropke, CD, 2011
)
0.37
" The purpose of this study was to evaluate the systemic pharmacokinetics, elimination, and oral bioavailability of KZ-41 in rats."( Preclinical pharmacokinetics of the radiomitigator KZ-41 in rats.
Miller, DD; Presley, CS; Thompson, KE; Yates, CR; Zeng, K, 2011
)
0.37
" This study is one of a series with the aim of determining possible effects of food matrices on caffeoylquinic acid (CQA) bioavailability using ileostomy volunteers."( Absorption and isomerization of caffeoylquinic acids from different foods using ileostomist volunteers.
Erk, T; Melcher, R; Renouf, M; Richling, E; Steiling, H; Williamson, G, 2014
)
0.88
"Our results show that variations in food matrices and variations in phenolic composition have a major influence on intestinal bioavailability and interesterification of the investigated subclass of polyphenols, the CQAs."( Absorption and isomerization of caffeoylquinic acids from different foods using ileostomist volunteers.
Erk, T; Melcher, R; Renouf, M; Richling, E; Steiling, H; Williamson, G, 2014
)
0.67
" Thus, specific data on their bioavailability in the upper gastrointestinal tract are of high interest, since some molecules are absorbed here and so are not metabolized by colonic microflora."( Structure- and dose-absorption relationships of coffee polyphenols.
Dionisi, F; Erk, T; Hauser, J; Renouf, M; Richling, E; Steiling, H; Williamson, G,
)
0.13
" Peak plasma concentration and urinary excretion values showed trends towards a reduced bioavailability of chlorogenic acids associated with the highest dose ingested, when expressed as percentages of intake."( Impact of dose on the bioavailability of coffee chlorogenic acids in humans.
Crozier, A; Stalmach, A; Williamson, G, 2014
)
0.4
" In this study, the potential for bioavailability of the artichoke polyphenols was estimated by using both in vitro digestion and Caco-2 human intestinal cell models."( Polyphenols from artichoke heads (Cynara cardunculus (L.) subsp. scolymus Hayek): in vitro bio-accessibility, intestinal uptake and bioavailability.
Cardinali, A; D'Antuono, I; Garbetta, A; Linsalata, V; Minervini, F, 2015
)
0.42
" Moreover, an in vitro gastrointestinal digestion model, applied to determine the effect of processing on the bioavailability of mulberry antioxidants, indicated a higher anthocyanin bioavailability for the fruit matrix than for the juice matrix."( The effects of juice processing on black mulberry antioxidants.
Beekwilder, J; Boyacioglu, D; Capanoglu, E; Hall, R; Tomas, M; Toydemir, G, 2015
)
0.42
" These effects are dependent on the bioavailability of chlorogenic acid, which is determined by the pharmacokinetic properties: absorption, distribution, metabolism and excretion (ADME)."( Demonstrating the involvement of an active efflux mechanism in the intestinal absorption of chlorogenic acid and quinic acid using a Caco-2 bidirectional permeability assay.
Hermans, N; Jörissen, J; Lebeer, S; Mortelé, O; Spacova, I; van Nuijs, ALN, 2021
)
0.83
" The in vivo intestinal absorption rate of chlorogenic acid (CA), the active component of the EEGS, both in a single form and in the EEGS were monitored by the single-pass intestinal perfusion (SPIP) method in rats."( Synergistic effects of trans-p-coumaric acid isolated from the ethanol extract of Gynura procumbens in promoting intestinal absorption of chlorogenic acid and reversing alcoholic fatty liver disease.
He, YM; Huang, XL; Li, YS; Mu, YM; Tang, HB; Wang, C, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" PTX-loaded QA-NP show greater anticancer efficacy than Taxol or PTX-loaded PEG-NP at the equivalent PTX dose in different animal models and dosing regimens."( Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins.
Jun, Y; Kim, P; Kron, SJ; Lee, SS; Lee, W; Pang, L; Seo, H; Xu, J; Yeo, Y; Zhang, RY; Zhang, ZY, 2018
)
1.92
" Boju fumigated with 7 different dosage of sulfur was conducted by HPLC analysis."( [Effect of different sulfur fumigation dosages on activity of browning enzymes and chemical constituents of Chrysanthemum morifolium cv. Boju].
Li, YL; Liang, YH; Wang, S; Wang, ZM; Zhu, JJ, 2019
)
0.51
" In order to have a better understanding of the biological properties of chlorogenic acid and to optimize formulation and dosing of chlorogenic acid-containing food supplements, information on the absorption of chlorogenic acid and its microbial biotransformation products is of essence."( Demonstrating the involvement of an active efflux mechanism in the intestinal absorption of chlorogenic acid and quinic acid using a Caco-2 bidirectional permeability assay.
Hermans, N; Jörissen, J; Lebeer, S; Mortelé, O; Spacova, I; van Nuijs, ALN, 2021
)
0.83
" These findings could aid in the development of optimal formulation and dosing strategies of chlorogenic acid in food supplements in order to obtain beneficial health effects."( Demonstrating the involvement of an active efflux mechanism in the intestinal absorption of chlorogenic acid and quinic acid using a Caco-2 bidirectional permeability assay.
Hermans, N; Jörissen, J; Lebeer, S; Mortelé, O; Spacova, I; van Nuijs, ALN, 2021
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (2)

PathwayProteinsCompounds
AtMetExpress overview0109
Lignin biosynthesis221

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency100.00000.631035.7641100.0000AID504339
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
gemininHomo sapiens (human)Potency18.35640.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amyloid-beta precursor proteinHomo sapiens (human)IC50 (µMol)100.00000.00053.889510.0000AID688479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amyloid-beta precursor proteinHomo sapiens (human)Activity1.20001.20005.600010.0000AID688483
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID338036Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamate pyruvate transaminase release at 1 mg/ml administered before 10 mins of carbon tetrachloride challenge measu
AID449329Cytotoxicity against human A549 cells after 2 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Synthesis and biological evaluation of quinic acid derivatives as anti-inflammatory agents.
AID106907Concentration that inhibits Human Immunodeficiency Virus Type 1 (HIV-1)-induced death of MT-2 cells1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID244024Inhibition of HL-60 cell adhesion to recombinant human Selectin P at 50 mM; Not active up to 100 mM2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Sialyl Lewis(x) analogs based on a quinic acid scaffold as the fucose mimic.
AID688483Inhibition of human amyloid beta (1 to 42) aggregates by measuring monomer concentration at 20 uM after 48 hrs by thermodynamic stability assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein.
AID338033Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 3 mg/ml administered before 10 mins of carbon tetrachloride challenge mea
AID402013Inhibition of collagenase type 52005Journal of natural products, May, Volume: 68, Issue:5
Collagenase inhibitory quinic acid esters from Ipomoea pes-caprae.
AID1248399Inhibition of alpha-amylase (unknown origin) relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
AID242319Inhibition of HL-60 cell adhesion to recombinant human Selectin E2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Sialyl Lewis(x) analogs based on a quinic acid scaffold as the fucose mimic.
AID688479Inhibition of human amyloid beta (1 to 42) aggregation after 24 hrs by thioflavin-T fluorescence assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein.
AID688484Inhibition of human amyloid beta (1 to 42) aggregation at 1 to 100 uM after 24 hrs by thioflavin-T fluorescence assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein.
AID338030Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 0.01 mg/ml administered before 10 mins of carbon tetrachloride challenge
AID338031Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 0.1 mg/ml administered before 10 mins of carbon tetrachloride challenge m
AID104233Lethal dose (LD5) concentration inhibiting growth of MT-2 cells by 5%1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID449328Antioxidant activity assessed as DPPH radical scavenging activity by UV-visible spectrophotometry2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Synthesis and biological evaluation of quinic acid derivatives as anti-inflammatory agents.
AID688486Inhibition of human amyloid beta (1 to 42) oligomerization assessed as decrease in trimer formation at 50 uM after 2 hrs by Western blot analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein.
AID338035Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic pyruvate transaminase release at 0.1 mg/ml administered before 10 mins of carbon tetrachloride challenge meas
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID242649Inhibition of HL-60 cell adhesion to recombinant human Selectin P; Not active up to 100 mM2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Sialyl Lewis(x) analogs based on a quinic acid scaffold as the fucose mimic.
AID91578Inhibition of Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration reaction at a concentration of 25 uM1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
AID338032Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic oxaloacetic transaminase release at 1 mg/ml administered before 10 mins of carbon tetrachloride challenge mea
AID244023Inhibition of HL-60 cell adhesion to recombinant human Selectin E at 50 mM; Not active up to 100 mM2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Sialyl Lewis(x) analogs based on a quinic acid scaffold as the fucose mimic.
AID338037Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic pyruvate transaminase release at 3 mg/ml administered before 10 mins of carbon tetrachloride challenge measur
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID338034Hepatoprotective activity against carbon tetrachloride-induced hepatotoxicity in fasted Sprague-Dawley rat hepatocytes assessed as serum glutamic pyruvate transaminase release at 0.01 mg/ml administered before 10 mins of carbon tetrachloride challenge mea
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Biochemistry, Feb-11, Volume: 53, Issue:5
Crystal structures of type I dehydroquinate dehydratase in complex with quinate and shikimate suggest a novel mechanism of Schiff base formation.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,042)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990151 (14.49)18.7374
1990's39 (3.74)18.2507
2000's211 (20.25)29.6817
2010's512 (49.14)24.3611
2020's129 (12.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.77 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index92.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (1.02%)5.53%
Reviews28 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,038 (96.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]